364 related articles for article (PubMed ID: 35172893)
1. Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome.
Lacombe V; Beucher A; Urbanski G; Le Corre Y; Cottin L; Croué A; Bouvier A
Exp Hematol Oncol; 2022 Feb; 11(1):6. PubMed ID: 35172893
[TBL] [Abstract][Full Text] [Related]
2. UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome.
Zakine E; Schell B; Battistella M; Vignon-Pennamen MD; Chasset F; Mahévas T; Cordoliani F; Adès L; Sébert M; Delaleu J; Jachiet M; Lepelletier C; Lemaire P; Chauvel C; Dhouaieb B; Kim R; Cassius C; Georgin-Lavialle S; Mekinian A; Bagot M; Braun T; Rousset L; Begon E; de Masson A; Fenaux P; Clappier E; Bouaziz JD
JAMA Dermatol; 2021 Nov; 157(11):1349-1354. PubMed ID: 34495287
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings.
Hines AS; Mohandesi NA; Lehman JS; Koster MJ; Cantwell HM; Alavi A; Warrington KJ; Mangaonkar AA; Go RS; Patnaik MM; Sartori-Valinotti JC
Int J Dermatol; 2023 Jul; 62(7):938-945. PubMed ID: 36890121
[TBL] [Abstract][Full Text] [Related]
4. VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist.
Sterling D; Duncan ME; Philippidou M; Salisbury JR; Kulasekararaj AG; Basu TN
J Am Acad Dermatol; 2023 Dec; 89(6):1209-1214. PubMed ID: 35121074
[TBL] [Abstract][Full Text] [Related]
5. Skin Manifestations of VEXAS Syndrome and Associated Genotypes.
Tan IJ; Ferrada MA; Ahmad S; Fike A; Quinn KA; Groarke EM; Beck DB; Allbritton J; Castelo-Soccio L; Young NS; Patel BA; Grayson PC; Cowen EW
JAMA Dermatol; 2024 Jun; ():. PubMed ID: 38865133
[TBL] [Abstract][Full Text] [Related]
6. VEXAS syndrome with cutaneous nodules.
Argobi Y
Dermatol Reports; 2022 Jun; 14(2):9414. PubMed ID: 35795842
[TBL] [Abstract][Full Text] [Related]
7. Vasculitis associated with VEXAS syndrome: A literature review.
Watanabe R; Kiji M; Hashimoto M
Front Med (Lausanne); 2022; 9():983939. PubMed ID: 36045928
[TBL] [Abstract][Full Text] [Related]
8. Clinical and histological features of histiocytoid Sweet syndrome associated with VEXAS syndrome.
Lecoeuvre H; Le Gall F; Le Naoures C; Vignon-Pennamen MD; Lamaison C; Kammerer-Jacquet SF; Lescoat A; Oger E; Pastoret C; Dupuy A
Clin Exp Dermatol; 2024 Feb; ():. PubMed ID: 38366665
[TBL] [Abstract][Full Text] [Related]
9. VEXAS syndrome.
Nakajima H; Kunimoto H
Int J Hematol; 2024 May; ():. PubMed ID: 38819628
[TBL] [Abstract][Full Text] [Related]
10. A case of VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) with decreased oxidative stress levels after oral prednisone and tocilizumab treatment.
Tozaki N; Tawada C; Niwa H; Mizutani Y; Shu E; Kawase A; Miwa Y; Ohnishi H; Sasai H; Miyako K; Hosokawa J; Kato A; Kobayashi K; Miyazaki T; Shirakami Y; Shimizu M; Iwata H
Front Med (Lausanne); 2022; 9():1046820. PubMed ID: 36544501
[TBL] [Abstract][Full Text] [Related]
11. VEXAS syndrome: A dermatological perspective.
Nguyen JK; Routledge D; van Der Weyden C; Blombery P; Angel CM; Johnson D; Goh MS; Lee A
Australas J Dermatol; 2022 Nov; 63(4):488-492. PubMed ID: 36197697
[TBL] [Abstract][Full Text] [Related]
12. Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.
Guerrero-Bermúdez CA; Cardona-Cardona AF; Ariza-Parra EJ; Arostegui JI; Mensa-Vilaro A; Yague J; Vásquez G; Muñoz-Vahos CH
Clin Rheumatol; 2022 Nov; 41(11):3565-3572. PubMed ID: 35986821
[TBL] [Abstract][Full Text] [Related]
13. VEXAS syndrome in dermatology.
Afsahi V; Christensen RE; Alam M
Arch Dermatol Res; 2023 Mar; 315(2):161-164. PubMed ID: 35201420
[TBL] [Abstract][Full Text] [Related]
14. VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder.
Huang H; Zhang W; Cai W; Liu J; Wang H; Qin T; Xu Z; Li B; Qu S; Pan L; Huang G; Gale RP; Xiao Z
Exp Hematol Oncol; 2021 Mar; 10(1):23. PubMed ID: 33741056
[TBL] [Abstract][Full Text] [Related]
15. VEXAS: is it time to reshape the nosology of clonal hematopoiesis?
Sujobert P; Largeaud L; Jamilloux Y; Heiblig M; Kosmider O
Expert Rev Hematol; 2023; 16(7):495-499. PubMed ID: 37119011
[TBL] [Abstract][Full Text] [Related]
16. VEXAS syndrome: An update.
Khitri MY; Hadjadj J; Mekinian A; Jachiet V
Joint Bone Spine; 2024 Feb; 91(4):105700. PubMed ID: 38307404
[TBL] [Abstract][Full Text] [Related]
17. VEXAS syndrome: Clinical manifestations, diagnosis, and treatment.
Loeza-Uribe MP; Hinojosa-Azaola A; Sánchez-Hernández BE; Crispín JC; Apodaca-Chávez E; Ferrada MA; Martín-Nares E
Reumatol Clin (Engl Ed); 2024 Jan; 20(1):47-56. PubMed ID: 38160120
[TBL] [Abstract][Full Text] [Related]
18. VEXAS Syndrome: A Novelty in MDS Landscape.
Templé M; Kosmider O
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885496
[TBL] [Abstract][Full Text] [Related]
19. Description of a novel splice site variant in UBA1 gene causing VEXAS syndrome.
Ospina Cardona D; Rodriguez-Pinto I; Iosim S; Bonet N; Mensa-Vilaro A; Wong MK; Ho G; Tormo M; Yagüe J; Shon W; Wallace D; Casals F; Beck DB; Abuav R; Arostegui JI
Rheumatology (Oxford); 2024 Mar; ():. PubMed ID: 38552317
[TBL] [Abstract][Full Text] [Related]
20. Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS.
Wu Z; Gao S; Gao Q; Patel BA; Groarke EM; Feng X; Manley AL; Li H; Ospina Cardona D; Kajigaya S; Alemu L; Quinones Raffo D; Ombrello AK; Ferrada MA; Grayson PC; Calvo KR; Kastner DL; Beck DB; Young NS
Cell Rep Med; 2023 Aug; 4(8):101160. PubMed ID: 37586319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
